title: Ondansetron in the treatment of cognitive decline in Alzheimer dementia.
abstract: The authors performed a multicenter, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of ondansetron (20 microg/day and 100 microg/ day) in treating cognitive decline in 185 patients with Alzheimer disease. Although ondansetron was well tolerated without any serious drug-related side effects, the study failed to demonstrate any significant cognitive improvement.
authors.affiliation: Geriatric Research, Education, and Clinical Center, Minneapolis VA Medical Center, Minneapolis, MN 55417, USA.
authors.forename: Maurice
authors.initials: M
authors.lastname: Dysken
authors.forename: Michael
authors.initials: M
authors.lastname: Kuskowski
authors.forename: Susan
authors.initials: S
authors.lastname: Love
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D009483:Neuropsychological Tests; D017294:Ondansetron / Q000009:adverse effects* / Q000627:therapeutic use*; D012702:Serotonin Antagonists / Q000009:adverse effects* / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D012702:Serotonin Antagonists; D017294:Ondansetron